Letters to the editor
=====================

Primary myelofibrosis (PMF) is a clonal stem cell disorder currently classified as a myeloproliferative neoplasm (MPN). The primary disease-causing mutation in PMF is unknown. Janus kinase 2 (*JAK2*) gain of function (*JAK2V617F*) and *MPL* gene mutation have been described in approximately 50% and 5%--10% of PMF patients, respectively \[[@B1]\]. Recently, the involvement of microRNA (miRNA) has been reported in PMF, showing a positive correlation with *JAK2V617F* allele burden \[[@B2]-[@B4]\]. miRNA are a class of single-stranded noncoding RNA that bind to the 3\'-untranslated region of target mRNA and suppress gene expression by translation repression or mRNA degradation. About 37% of miRNA appear to be located within introns of protein-coding genes and may be transcribed by their own promoters or by the host gene promoter with a correlated expression \[[@B5]\]. Many miRNA target genes show expression patterns that are significantly correlated with the expression of the miRNA host genes \[[@B5]\].

We describe here a PMF case evolving to acute myeloid leukemia (AML) with a t(12;18)(p13;q12) rearrangement, showing *SETBP1* overexpression and downregulation of intronic miR_4319. The expression dysregulation increased during PMF progression, suggesting the involvement of a novel molecular mechanism in the leukemogenesis.

Case presentation
=================

A 75-year-old man came to our attention in July 2008 with symptoms of anemia, leukocytosis, and splenomegaly. Peripheral blood analysis showed leukoerythroblastosis and a bone marrow biopsy revealed a megakaryocyte proliferation with atypia, together with reticulin fibrosis. Conventional cytogenetic analysis showed the following karyotype: 46,XY\[20\]. Molecular analysis excluded the presence of the 5*\'BCR/3\'ABL* transcript whereas *JAK2V617F* was detected. In accordance with World Health Organization (WHO) 2008 criteria, a diagnosis of PMF was made. Treatment with hydroxyurea was started. In August 2009, the patient showed a raised leukocytes count. A bone marrow aspirate detected 30% of the myeloid blasts, giving rise to the diagnosis of AML. Cytogenetic analysis revealed the following karyotype: 46,XY,t(12;18)(p13;q12)\[20\]. Molecular analysis demonstrated the presence of the *JAK2* wild-type gene. Treatment with low dose ARA-C was started but the patient died a few days later of disease progression.

Fluorescence *in situ* hybridization (FISH) analysis was performed at the onset of the AML diagnosis using bacterial artificial chromosome (BAC) probes selected according to the University of California Santa Cruz (UCSC) database (<http://genome.ucsc.edu/index.html>; February 2009 release). This analysis showed the occurrence of a t(12;18)(p13.2;q12.3) rearrangement with breakpoints mapping inside *ETV6* on chromosome 12 and inside *BCO51727* on chromosome 18 (Figure [1](#F1){ref-type="fig"}A, B). Notably, the chromosome 12 breakpoint was mapped between the BAC clones RP11-639O1 and RP11-418C2 (12p13.2), whereas the clones RP11-951D16 and RP11-840B16 (18q12.3) delimited the breakpoint region on chromosome 18 (Figure [1](#F1){ref-type="fig"}A). At the PMF onset, FISH did not reveal the presence of the t(12;18) rearrangement.

![**FISH and molecular characterization of the t(12;18)(p13.2;q12.3) rearrangement. (A)** FISH analysis showing chromosome 12 and 18 breakpoints identification in the follow-up sample (on the left). A schematic representation of genes and BAC clones used in molecular cytogenetic experiments is shown (on the right). **(B)** RT-PCR experiments showing *5\'ETV6/3\'BCO51727* produced by the fusion of *ETV6* exon 1 with *BC051727* exon 3 (underlined). A truncated fusion protein was generated.](1756-8722-5-48-1){#F1}

Reverse transcription PCR (RT-PCR) experiments performed to verify the occurrence of possible fusion genes involving *ETV6* and *BCO51727* showed a *5\'ETV6/3\'BCO51727* fusion transcript using primers mapping inside *ETV6* exon 1 (5\'GGGAGAGATGCTGGAAGAAACT3\') and *BCO51727* exon 4 (5\'AAGCCCAATGTTTCAAGACCTC3\'). The *5\'ETV6/3\'BCO51727* fusion gene was shown to be constituted by *ETV6* exon 1 joined to *BCO51727* exons 3, 4, and 5 (Figure [1](#F1){ref-type="fig"}B).

This breakpoint was different from the one previously reported, but a truncated protein was produced resulting from the presence of premature stop codons (Figure [1](#F1){ref-type="fig"}B). No reciprocal *5\'BCO51727/3\'ETV6* fusion transcript was detected (data not shown). As the t(12;18) breakpoints were located about 300 kbp centromerically to *SETBP1* (18q12.3), we analyzed the gene expression by quantitative real-time PCR (qRT-PCR) experiments. The β-glucuronidase (*β-GUS*) gene was selected as an endogenous control and a pool of cDNA derived from bone marrow cells of ten healthy individuals was used as calibrator. This analysis showed *SETBP1* overexpression by a mean factor of 1.54 and 2.88 in samples at the onset of PMF and at progression to AML, respectively (Figure [2](#F2){ref-type="fig"}A).

![**Results of qRT-PCR studies. Graphic representation of*SETBP1*(A) and miR_4319 (B) expression detected in the onset and follow-up samples of the analyzed patient and in normal bone marrow samples (NBM).**](1756-8722-5-48-2){#F2}

The UCSC database was queried at the "sno/miRNA" track to verify the presence of miRNA close to the t(12;18) breakpoints; interestingly, miR_4319 mapped inside intron 4 of *SETBP1*. miRNA expression analysis was performed by qRT-PCR with a specific primer pair, Hs miR-4319 miScript Primer Assay, and RNU6B miScript Primer Assay for normalization (Qiagen). qRT-PCR experiments showed downregulation of miR_4319 by a mean factor of 0.35 and 0.18 at PMF onset and progression to AML, respectively (Figure [2](#F2){ref-type="fig"}B). A query of the MicroCosm (<http://www.ebi.ac.uk/enright-srv/microcosm/>) and TargetScan (<http://www.targetscan.org/>) databases did not elicit any predicted target genes of miR_4319.

Conclusions
===========

We report, for the first time, concomitant dysregulation of *SETBP1* and of its intronic miRNA in a PMF case evolving to AML showing a t(12;18)(p13.2;q12.3) rearrangement. To date, *SETBP1* overexpression has been described as a recurrent molecular event in 27.6% of AML patients at diagnosis, playing a crucial role in the leukemic transformation through the protein phosphatase 2A inhibition \[[@B6],[@B7]\]. By contrast, the involvement of miR_4319 has never been previously demonstrated in AML.

It is known that intronic miRNA and host genes could show a correlative or discordant expression \[[@B5]\]. Several possible mechanisms could explain host-gene-independent expression, such as different transcript stabilities, post-transcriptional miRNA regulation, or the presence of a specific miRNA promoter \[[@B5],[@B8]\]. In our case, the unrelated expression and opposite orientation between miR_4319 and *SETBP1* suggest the existence of different, independent promoters.

Moreover, the occurrence of *SETBP1* and miR_4319 dysregulation in the sample at diagnosis suggests the presence of the leukemic clone at too low a level to be detected by FISH. The disappearance during PMF progression of *JAK2V617F* at the same time as the leukemic clone expansion suggests an outstanding pathogenetic role for *SETBP1* and miR_4319 in PMF evolution to AML.
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